准IRE1α重新编程瘤微环境,并增强前列腺癌的抗瘤免疫力
Bilal Unal1,2, Omer Faruk Kuzu1,2, Yang Jin1
1Department of Biosciences, University of Oslo, Oslo, Norway.
Nature communications
|October 15, 2024
概括
准IRE1α信号传递,这是未展开的蛋白质反应 (UPR) 的一个关键部分,抑制前列腺癌的生长. 这种方法还可以增强抗瘤免疫力,提高免疫疗法的有效性.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 展开的蛋白质反应 (UPR) 是细胞应激途径,对细胞生存至关重要.
- 瘤细胞利用UPR通路,包括IRE1α信号传递,以促进它们的生长和生存.
- 前列腺癌 (PCa) 的进展与失调的细胞应激反应有关.
研究的目的:
- 为了研究 IRE1α 信号在前列腺癌中的作用.
- 评估在PCa中抑制IRE1α的治疗潜力.
- 确定IRE1α抑制对瘤微环境 (TME) 和抗瘤免疫的影响.
主要方法:
- 在PCa患者瘤中IRE1α信号的分析.
- 在临床前的PCa模型中使用基因和小分子方法抑制IRE1α.
- 单细胞RNA测序以分析TME变化.
- 评估免疫系统激活和抗瘤反应.
主要成果:
- 在PCa瘤中,IRE1α信号传递升高.
- 在临床前模型中,抑制IRE1α可以减少PCa瘤的生长.
- 准IRE1α增强了干扰素反应,并激活了TME中的与免疫相关的途径.
- IRE1α抑制降低了与瘤相关的巨细胞的丰富性.
- IRE1α抑制剂MKC8866重新编程TME并增强抗PD-1疗法的疗效.
结论:
- IRE1α信号传递促进PCa细胞的生长和存活.
- IRE1α信号干扰了TME内的抗瘤免疫.
- 准IRE1α是一个有前途的策略,可以增强前列腺癌的抗PD-1免疫疗法.
更多相关视频
12:13Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019
6.8K
09:11Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
394
相关概念视频
Tumor Immunotherapy
488
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
488
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Regulation of the Unfolded Protein Response
2.4K
Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
2.4K
The Tumor Microenvironment
6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
Experimental RNAi
6.1K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.1K
